Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer
Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.
Related Articles
Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.
PER® Winter Lung Cancer Conference
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
ADC Development in Ovarian Cancer: What’s Next for FRa and Beyond?
Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.
Targeted Oncology – Immunotherapy, Biomarkers, and Cancer Pathways
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Trifluridine/Tipiracil Benefits Stage IV CRC With Molecular Residual Disease
Trifluridine/tipiracil improved DFS in stage IV CRC with molecular residual disease but not in the full ALTAIR study population.
Burnout in US Oncologists Increased Over the Past 10 Years, Data Suggest
Burnout, emotional exhaustion, and depersonalization were more common in a 2023 survey than in a 2013 survey.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Dr. David S. Hong presents the preliminary Phase 1 results on RMC-9805, a first-in-class, oral, RAS(ON) G12D-selective inhibitor, highlighting its promising safety, pharmacokinetics, and early…